DDW Editor Reece Armstrong speaks to Dr Carlos Buesa, Founder and CEO of Oryzon Genomics, about epigenetic approaches to treating cancer and the company’s current journey within drug discovery and development. RA: Can an epigenetic approach help tackle aggressive cancers and those with poor prognoses? CB: Yes. Many aggressive cancers are driven not only by gene mutations, but by the way those mutations disrupt the epigenetic machinery that […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!